(57 days)
The cassette COBAS Integra Serum Benzodiazepines contains and in vitro diagnostic reagent system intended for use on the COBAS INTEGRA analyzer for the detection of Benzodiazepines and their metabolites in human serum, heparinized plasma or urine. This reagent system is intended for use in toxicological screenings where the analytical result is used in the management of benzodiazepine use or overdose.
Not Found
This is an FDA 510(k) clearance letter for an in vitro diagnostic device, not a study report for an AI/ML device. Therefore, the requested information about acceptance criteria, study design, and performance metrics for AI/ML devices cannot be extracted from this document.
The document indicates that the device, "Roche COBAS INTEGRA Serum Benzodiazepines (SBENZ)," is deemed "substantially equivalent" to legally marketed predicate devices, which is the regulatory standard for 510(k) clearance. This means the device performs at least as well as existing, approved devices for the stated indications for use.
Here's what can be gathered from the provided text, but it does not align with the requested format for AI/ML device studies:
- Device Name: Roche COBAS INTEGRA Serum Benzodiazepines
- Intended Use: Detection of Benzodiazepines and their metabolites in human serum, heparinized plasma, or urine on the COBAS INTEGRA analyzer for toxicological screenings where the analytical result is used in the management of benzodiazepine use or overdose.
- Regulatory Class: II
- Product Code: JXM
- FDA Decision: Substantially Equivalent to predicate devices.
To answer your specific questions in the context of an AI/ML device, the provided text does not contain:
- A table of acceptance criteria and reported device performance: This document does not describe specific performance metrics (e.g., sensitivity, specificity, accuracy) or their acceptance thresholds.
- Sample size used for the test set and data provenance: Not mentioned.
- Number of experts used to establish ground truth and their qualifications: Not applicable for a traditional in vitro diagnostic device regulatory submission of this type.
- Adjudication method for the test set: Not applicable.
- MRMC comparative effectiveness study or effect size: Not applicable. This is not an AI/ML device, and no human-in-the-loop study is described.
- Standalone performance (algorithm only): Not applicable for this type of device.
- Type of ground truth used: Not explicitly stated, but for a benzodiazepine detection assay, the ground truth would typically come from a reference method (e.g., GC-MS or LC-MS) of known accuracy.
- Sample size for the training set: Not applicable, as this is a chemical assay, not a machine learning model.
- How the ground truth for the training set was established: Not applicable.
In summary, this document is a regulatory clearance letter for a traditional in vitro diagnostic device, not a study report for an AI/ML-driven medical device. Therefore, the information requested regarding AI/ML device acceptance criteria and study details is not present.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized depiction of a human figure, represented by three curved lines that suggest a head, body, and legs. The logo is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" arranged in a circular fashion around the figure.
Public Health Service
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 2 2 1999
Ms. Lisa M. Gerard Regulatory Affairs Consultant Roche Diagnostics Corporation 9115 Hague Road PO Box 50457 Indianapolis, Indiana 46250-0457
Re: K991443
Trade Name: Roche COBAS INTEGRA Serum Benzodiazepines (SBENZ) Regulatory Class: II Product Code: JXM Dated: April 23, 1999 Received: April 26, 1999
Dear Ms. Gerard:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use Statement
:
| 510(k) Number (if known): | K 991443 |
|---|---|
| Device Name: | Roche COBAS INTEGRA Serum Benzodiazepines |
| Indications for Use: | The cassette COBAS Integra Serum Benzodiazepines contains and in vitro diagnostic reagent system intended for use on the COBAS INTEGRA analyzer for the detection of Benzodiazepines and their metabolites in human serum, heparinized plasma or urine. This reagent system is intended for use in toxicological screenings where the analytical result is used in the management of benzodiazepine use or overdose. |
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use (Per 21 CFR 801.109) | OR | Over-the-Counter Use |
|---|---|---|
| --------------------------------------- | ---- | ---------------------- |
(Optional format 1-2-96)
Jean Cooper
(Division Sign-Off)
Division of Clinical Laboratory, vice
510(k) Number K991443
§ 862.3170 Benzodiazepine test system.
(a)
Identification. A benzodiazepine test system is a device intended to measure any of the benzodiazepine compounds, sedative and hypnotic drugs, in blood, plasma, and urine. The benzodiazepine compounds include chlordiazepoxide, diazepam, oxazepam, chlorzepate, flurazepam, and nitrazepam. Measurements obtained by this device are used in the diagnosis and treatment of benzodiazepine use or overdose and in monitoring levels of benzodiazepines to ensure appropriate therapy.(b)
Classification. Class II (special controls). A benzodiazepine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).